References
- Foxman B. Urinary tract infection syndromes. Occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin North Am. 2014;28(1):1–13.
- Flores-Mireles AL, Walker JN, Caparon M, et al. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015;13(5):269–284.
- UN. Contraceptive use by method. World contraceptive use 2019. 2019.
- Fihn SD, Boyko EJ, Chen CL, et al. Use of spermicide-coated condoms and other risk factors for urinary tract infection caused by Staphylococcus saprophyticus. Arch Intern Med. 1998;158(3):281–287.
- Achilles S, Hillier S. The complexity of contraceptives: understanding their impact on genital immune cells and vaginal microbiota. AIDS. 2013;27(Supplement 1): S5–S15.
- Eschenbach D, Patton D, Meier A, et al. Effects of oral contraceptive pill use on vaginal flora and vaginal epithelium. Contraception. 2000;62(3):107–112.
- Hooton T, Hillier S, Johnson C, et al. Escherichia coli bacteriuria and contraceptive method. JAMA. 1991;265(1):64–69.
- Hooton T, Scholes D, Hughes J, et al. A prospective study of risk factors for symptomatic urinary tract infection in young women. N Engl J Med. 1996;335(7):468–474.
- Lo C, Abraham A, Lipworth L, et al. Intrauterine devices as an exposure risk for urinary tract infections: a scoping review. Am J Reprod Immunol. 2021;13476.
- Perrotta C, Aznar , Meija R. Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev. 2008;:CD005131.
- Rozenberg S, Pastijn A, Gevers R, et al. Estrogen therapy in older patients with recurrent urinary tract infections: a review. Int J Women Fertil Med. 2004;49:71–74.
- Hubacher D. Intrauterine devices & infection: review of the literature. Indian J Med Red. 2014;140:S53–S57.
- Roden D, Pulley J, Basford M, et al. Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin Pharmacol Ther. 2008;84(3):362–369.
- Schildcrout JS, Denny JC, Bowton E, et al. Optimizing drug outcomes through pharmacogenetics: a case for preemptive genotyping. Clin Pharmacol Ther. 2012;92(2):235–242.
- Wurzinger B, Dunser M, Wohlmuth C, et al. The association between body-mass index and patient outcome in septic shock: a retrospective cohort study. Wien Klin Wochenschr. 2010;122(1–2):31–36.
- Bochicchio G, Joshi M, Bochicchio K, et al. Impact of obesity in the critically ill trauma patient: a prospective study. J Am Coll Surg. 2006;203(4):533–538.
- Scholes D, Hooton TM, Roberts PL, et al. Risk factors for recurrent urinary tract infection in young women. J Infect Dis. 2000;182(4):1177–1182.
- Albracht C, Hreha T, Hunstad D. Sex effects in pyelonephritis. Pediatr Nephrol. 2021;36(3):507–515.
- Robinson D, Cardozo L. Estrogens and the lower urinary tract. Neurourol Urodyn. 2011;30(5):754–757.
- Burger HG, Hale GE, Robertson DM, et al. A review of hormonal changes during the menopausal transition: focus on findings from the Melbourne women’s midlife health project. Hum Reprod Update. 2007;13(6):559–565.
- AuroMedics Pharma LLC. Medroxyprogesterone injection. Medroxyprogesterone package insert; 2021. p. 1–2.
- Cunha J. Etonogestrel implant. RxList. 2022;1–3.
- Cooper D, Patel P, Mahdy H. Oral contraceptive pills. StatPearls [Internet]; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430882/?report=classic.
- Bastarache L, Brown JS, Cimino JJ, et al. Developing real-world evidence from real-world data: transforming raw data into analytical datasets. Learn Health Syst. 2022;6(1):e10293.